Related Experiment Video
Updated: May 10, 2026
10:34
Measurement of Differentially Methylated INS DNA Species in Human Serum Samples as a Biomarker of Islet β Cell Death
Published on: December 21, 2016
Novel biomarkers in type 1 diabetes
1Center for Biotechnology and Genomic Medicine and Department of Pathology, Medical College of Georgia, Georgia Regents University, Augusta, GA 30912, USA.
The Review of Diabetic Studies : RDS
|June 28, 2013
Summary
Developing new biomarkers for type 1 diabetes (T1D) is crucial for early prediction and monitoring. Current markers like susceptibility genes and autoantibodies have limitations, driving the search for improved diagnostic tools.
Area of Science:
- Biomedical research
- Immunology
- Genetics
Background:
- Biomarkers are vital for understanding type 1 diabetes (T1D) pathogenesis, predicting risk, and monitoring treatment.
- Current T1D biomarkers, including susceptibility genes and islet autoantibodies, have limitations in specificity, sensitivity, and early detection.
Purpose of the Study:
- To review the progress, opportunities, and challenges in discovering novel biomarkers for type 1 diabetes.
- To highlight the importance of genetic, transcriptomic, and proteomic approaches in T1D biomarker development.
Main Methods:
- Review of existing literature on T1D biomarker research.
- Focus on high-throughput technologies including genetic, transcriptomic, and proteomic studies.
- Analysis of genome-wide examinations in T1D patients and prediabetic subjects.
Main Results:
- Numerous susceptibility genes and gene/protein expression changes have been identified.
- Despite extensive research, no definitive "star biomarker" for T1D has emerged.
- Existing biomarkers lack the desired specificity, sensitivity, and utility for early prediction or therapeutic assessment.
Conclusions:
- Significant improvements in study design and analytical methods are needed to identify clinically relevant T1D biomarkers.
- Prospective studies are essential to evaluate the clinical benefits of newly discovered biomarker candidates.
- Future research should focus on refining methodologies to discover effective T1D biomarkers for risk prediction and therapeutic monitoring.
Related Concept Videos
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.